CONCLUSIONS.: In this retrospectie analysis, induction with alemtuzumab did not increase the rate of re-emergence of autoantibodies or biopsy-proen recurrence of glomerular disease.

• 结论：在这项回顾性研究分析中，阿仑单抗免疫诱导并不会增加自身抗体的再次出现率或者活组织检查肾小球疾病的复发率。